Ossiform

Monica Wellejus, and Gijs Klarenbeek, will attend the annual EFAS (European Foot & Ankle Society) Congress, taking place in Augsburg, Germany on October 1-3.

The Ossiform delegation is looking forward to exploring the latest developments in Foot & Ankle surgery, connecting with physicians and industry, and broadening our European network within Foot & Ankle surgery 🦶

If you are interested in meeting, please reach out to Monica at [email protected].

At Ossiform, we pride ourselves on providing researchers with a standardized platform for their bone research, helping them achieve physiologically relevant results in an optimized environment. Since the most valuable feedback comes from our customers and the end-users of our products, we are delighted to share this testimonial from a researcher who has been using the P3D Scaffolds:

"We have been using the Ossiform grid 5 mm diameter scaffolds in our 3D bone models for the past six months and have been very satisfied with both the products and the customer support we have received. The uniformity of the scaffolds has added a level of standardization to our model that was not possible with our previous scaffolds. For example, the Ossiform scaffolds have allowed us to optimize our cell seeding density with much greater precision. The uniformity of the scaffolds has also been beneficial for longitudinal uCT imaging, allowing us to track changes in our model over time.

In addition, the customer support from Ossiform has been outstanding. Our representative took the time to meet with our team to discuss the needs of our project and recommend the most suitable product. We were provided with trial scaffolds for evaluation, and Ossiform remained responsive throughout the selection, ordering, and implementation process. They have continued to follow up to ensure that we are satisfied with the products and to answer any questions that arise. We would highly recommend Ossiform to researchers looking for high-quality, standardized scaffolds and excellent customer support."

- Madison Skye Chacon
Bioenergetics, Glucocorticoids & 3R-Research
Charité - University of Medicine Berlin

Thank you for your kind words and for choosing Ossiform as part of your research journey. We are proud to support researchers worldwide with innovative scaffold solutions and look forward to seeing the exciting discoveries their work will lead to 🦴

Ossiform is at TechBBQ today!

If you are around, come over for a chat with our CEO, Thea Wulff Olesen and Product Specialist, Pernille Yde Øhlenschlæger Nielsen.

You will find us in the Life Science Invest area 🦴

TechBBQ

See you at TechBBQ 2026!

Ossiform CEO, Thea Wulff Olesen, and Product Specialist, Pernille Øhlenschlæger, will attend this year’s TechBBQ on August 27 in Bella Center, Copenhagen.

TechBBQ has become one of Europe’s leading startup and innovation events, bringing together founders, investors, researchers, industry leaders, and tech professionals to explore new ideas, build partnerships, and shape the future of technological innovation.

At Ossiform, we are dedicated to improving the lives of people with bone defects with 3D printed, bio-integrative bone substitute solutions. Events like TechBBQ provide an amazing opportunity to connect with other innovators and tech investors to discuss how breakthrough technologies can create real clinical impact.

If you are attending TechBBQ and would like to learn more about Ossiform, we would love to meet with you there.

We are pleased to share that Ossiform has been invited to present at Lux Research's upcoming Ideathon on Biomedical Materials & Composites, taking place on July 7, 2026 🦴

As a company operating at the intersection of 3D printed biomaterials and tissue engineering, Ossiform is committed to advancing dialogue around emerging materials technologies and their applications in orthopedic care. Events such as the Lux Research Ideathon provide a valuable opportunity to connect with researchers, innovators, and industry leaders to discuss how biomaterials and composites can help shape the next generation of orthopedic solutions.

Our CCO, Monica Wellejus, will represent the company and contribute to discussions alongside leading experts exploring new developments and opportunities within the fields of biomaterials and orthopedics💡

We look forward to contributing to the event and supporting the continued evolution of regenerative and orthopedic technologies.

Learn more about Lux Research: https://luxresearchinc.com/overview/

📢 Newsletter launch tomorrow, and a sneak peek 👀

The first edition of our quarterly newsletter is released tomorrow, July 1. If you haven’t signed up yet, you can still make it!

We will be sharing Ossiform’s progress over the last quarter, upcoming activities and events, and key priorities in the coming months.

If you want to follow along, subscribe to the newsletter here: https://lnkd.in/eSFRMk42.

We’re excited to announce that Ossiform has partnered with Imbros as our new distributor for Australia and New Zealand🌏

With over 50 years of experience supplying scientific instruments across Oceania, Imbros has a strong track record of delivering innovative technologies to market, making them an ideal partner to support the distribution of Ossiform’s P3D Scaffolds in the region.

Through this collaboration, we aim to empower more researchers to explore new possibilities in bone research and tissue engineering🦴

We look forward to working with the Imbros team to support the scientific community across Australia and New Zealand.

🔗 Learn more about Imbros: https://imbros.com.au/product/ossiform-p3d-scaffolds/

How can bone-mimicking scaffolds be used in cancer research? 🦴

While cancer research has come far with the use of traditional 2D cell cultures and various animal models, three-dimensional tumor models – also called tumoroids – are an emerging tool within the field.

Tumoroids have the ability to replicate key features of the tumor micro-environment, which in turn offer a more physiologically relevant disease model that retains the biological characteristics of the primary tumor🧫

Tumoroids are typically derived from patient cancer cells or immortalized cancer cell lines and they can enable:
- Studies of tumor-matrix interactions
- Evaluation of anticancer therapies
- Investigation of metastatic mechanisms

Many solid tumors and cancer types – including breast and prostate cancer – metastasize to our bones. Yet bone metastasis remains one of the most difficult aspects of cancer biology to model in vitro due to the complexity of the tissue.
By providing a mineralized, bone-mimicking microenvironment, the P3D Scaffolds from Ossiform enable researchers to grow 3D tumoroids that accurately replicate the tumor-host tissue interactions in a physiologically relevant setting without the use of animal models🐀

Such bone cancer model makes it possible to:
- Investigate how cancer cells colonize and adapt to bone
- Study metastatic mechanisms in a controlled system
- Screen anticancer therapies with improved translational relevance

As the field moves toward scalable, human-relevant research platforms, tumoroids represent a powerful alternative to traditional 2D cultures and many animal models.

Learn more about how P3D Scaffolds and tumoroids advance bone metastasis research and therapeutic development: https://ossiform.com/how-miniature-tumors-can-be-grown-on-p3d-scaffolds-for-cancer-research/

What have we been up to lately?
Short answer: quite a lot.

We are launching a quarterly newsletter to share what we have been working on, our progress across key initiatives, and where we are headed next. Each edition brings highlights from the past quarter and a preview of what is coming.

If you would like a closer look at how Ossiform is evolving, you are very welcome to join.

Subscribe via our website or use the form linked below to follow along 👇

Ossiform news: https://ossiform.com/press-releases-and-news/
Direct link to the sign-up form: https://2fzpgw.share-eu1.hsforms.com/2qMP6Ooe5RPmoUKvvUC9gbA